We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

0 hedge funds and large institutions have $0 invested in Aimmune Therapeutics in 2020 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 188 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 188 → 0 (-188)

100% less funds holding in top 10

Funds holding in top 10: 9 → 0 (-9)

100% less capital invested

Capital invested by funds: $1.49B → $0 (-$1.49B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 188

Holders
–
Holders Change
-188
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
188
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$143M
2
BlackRock
BlackRock
New York
-$129M
3
PCM
Pentwater Capital Management
Florida
-$86.2M
4
Goldman Sachs
Goldman Sachs
New York
-$75.8M
5
AAM
Alpine Associates Management
Florida
-$71.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Canada Life
151
Canada Life
Manitoba, Canada
– -$99K -2,879 Closed
QT
152
Quantbot Technologies
New York
– -$96K -2,810 Closed
Osaic Holdings
153
Osaic Holdings
Arizona
– -$96K -2,801 Closed
GT
154
Glenmede Trust
Pennsylvania
– -$68K -2,000 Closed
Rockefeller Capital Management
155
Rockefeller Capital Management
New York
– -$60K -1,754 Closed
Macquarie Group
156
Macquarie Group
Australia
– -$56K -1,618 Closed
AA
157
Ancora Advisors
Ohio
– -$43K -1,253 Closed
CLOS
158
Compagnie Lombard Odier SCmA
Switzerland
– -$34K -1,000 Closed
FIA
159
FNY Investment Advisers
New York
– -$31K -900 Closed
APA
160
American Portfolios Advisors
New York
– -$24.1K -700 Closed
Fidelity Investments
161
Fidelity Investments
Massachusetts
– -$20K -584 Closed
PCM
162
Penserra Capital Management
California
– -$19K -560 Closed
Daiwa Securities Group
163
Daiwa Securities Group
Japan
– -$12K -357 Closed
Fifth Third Bancorp
164
Fifth Third Bancorp
Ohio
– -$12K -347 Closed
CG
165
Cutler Group
California
– -$10K -300 Closed
PNC Financial Services Group
166
PNC Financial Services Group
Pennsylvania
– -$7K -212 Closed
JCM
167
Jacobi Capital Management
Pennsylvania
– -$7K -200 Closed
ASN
168
Advisory Services Network
Georgia
– -$6K -164 Closed
LC
169
Lindbrook Capital
California
– -$5K -156 Closed
BCA
170
Berman Capital Advisors
Georgia
– -$5K -150 Closed
PFGIA
171
Patriot Financial Group Insurance Agency
Massachusetts
– -$5K -140 Closed
PA
172
Parallel Advisors
California
– -$3K -101 Closed
CAPTRUST Financial Advisors
173
CAPTRUST Financial Advisors
North Carolina
– -$3K -100 Closed
CFD
174
Creative Financial Designs
Indiana
– -$3K -75 Closed
SFS
175
Sowell Financial Services
Arkansas
– -$2K -58 Closed
4 5 6
7
8

AIMT Hedge Fund Activity: Q4 2020 in Review

0 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q4 2020, worth a combined $0 — down 100% from $1.49B a quarter earlier.

Sellers outnumbered buyers: 188 funds closed out of AIMT and 0 opened new positions — a net loss of 188 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $143M sold.

  • 0 institutional investors held Aimmune Therapeutics (AIMT) as of Q4 2020, down from 188 in Q3 2020.
  • Funds reported $0 of Aimmune Therapeutics stock for Q4 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Aimmune Therapeutics positions in Q4 2020 and 188 closed out, a net change of -188 holders.
  • The largest Aimmune Therapeutics seller in Q4 2020 was Vanguard Group, an estimated $143M sold.

Based on aggregated 13F filings for Q4 2020.